ABOUT US
A global leader in innovative genomic
technology and diagnostic tests.
What’s new at Agendia?
Get the latest updates on our company and products, as well as new developments in genomic science.
News
In the News
News
Media Releases
Agendia Demonstrates Accessibility and Affordability of MammaPrint and BluePrint in Europe at ESMO Breast Cancer 2022
Next-generation sequencing version of MammaPrint and BluePrint enables decentralized testing in CE-mark jurisdictions like Germany Analysis for Belgian Health Care Package shows MammaPrint yields cost-savings for breast cancer care systemically IRVINE, Calif. & AMSTERDAM--(BUSINESS WIRE)--Agendia, Inc., Read More
Agendia to Deliver Robust Suite of Data Advancing Breast Cancer Care at ASCO 2022
Company showcases pipeline developments and sub-studies from the revolutionary FLEX Registry with posters focused on patient-centric insights Two oral discussion sessions to focus on RUO ImPrint immune signature and BluePrint® whole transcriptomic analysis in Black Read More
GenomeWeb – Agendia Offering AI-Enabled Genomic Test for Breast Cancer in Brazil as it Eyes Global Market
January 27, 2022 By Leo O’Connor NEW YORK ─ As part of its effort to gain regulatory clearance in the US and beyond, Agendia has begun offering early access to a digital testing platform for patients Read More
Agendia Study Demonstrates MammaPrint® and BluePrint® Capture Full Spectrum of Early Breast Cancer Biology, Providing Opportunity for Highly Individualized Treatment
New analysis in peer-reviewed journal Genes, Chromosomes and Cancer further establishes that MammaPrint and BluePrint both comprehensively represent and capture the 10 hallmarks of cancer in early-stage breast cancer Study validates genomic basis of Read More
